Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Thalassemia × Alemtuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia 27 Leukemia, Lymphocytic, Chronic, B-Cell 24 Lymphoma 16 Myelodysplastic Syndromes 11 Hodgkin Disease 11 Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Multiple Myeloma 7 Leukemia, Myeloid, Acute 7 Lymphoma, Non-Hodgkin 6 Lymphoma, Follicular 6 Recurrence 5 Myeloproliferative Disorders 5 Lymphoma, Mantle-Cell 5 Lymphoma, Large B-Cell, Diffuse 5 Leukemia, Myeloid, Chronic-Phase 5 Hematologic Neoplasms 5 Lymphoma, T-Cell, Cutaneous 4 Lymphoma, B-Cell, Marginal Zone 4 Anemia, Aplastic 4 Waldenstrom Macroglobulinemia 3 Sezary Syndrome 3 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3 Mycosis Fungoides 3 Lymphoma, T-Cell, Peripheral 3 Lymphoma, Large-Cell, Anaplastic 3 Lymphoma, Extranodal NK-T-Cell 3 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3 Leukemia, Large Granular Lymphocytic 3 Immunoblastic Lymphadenopathy 3 Hematologic Diseases 3

Interventions

fludarabine phosphate 2 Cyclophosphamide 2 fludarabine 1 Whole-Body Irradiation 1 Peripheral Blood Stem Cell Transplantation 1 Mesna 1 Busulfan 1 Alemtuzumab 1 AP 1903 reagent 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00578292 2020-05-01

THALLO

Baylor College of Medicine

Phase NA Terminated

10 enrolled 15 charts

Lymphoma, Follicular, Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon ⚡